陽明大學臨床醫學研究所博士
   陽明大學醫學士

   臺北榮總心臟衰竭中心主任
   臺北榮民總醫院內科部心臟內科主治醫師

   國立陽明交通大學內科學科教授

• 中華民國心臟學會/臺灣高血壓學會2010, 2015, 2017高血壓治療指南主席及第一作者
• 臺灣心律學會/臺灣心臟學會2016心房顫動治療指南主席及第一作者
• 亞太心律學會(APHRS) 2017心房顫動中風預防指南主席及第一作者
• 中華民國心臟學會/中華民國糖尿病學會2018糖尿病合併心血管病治療指南主席及第一作者
• 中華民國心臟學會2020糖尿病合併心血管病治療指南主席及第一作者
• 中華民國心臟學會2021糖尿病新藥共識路徑主席及第一作者
• 中華民國心臟學會/臺灣高血壓學會2022高血壓治療指南共同第一作者
• 亞洲2022心房顫動中風預防共識主席及第一作者
• 中華民國心臟學會2023心臟衰竭藥物治療共識主席及第一作者
• 中華民國心臟學會2023慢性冠心病治療指南共同主席

• 臨床試驗、臨床藥理學
• 心臟學
• 心電生理學
• 臨床及基礎心律不整
• 著作：國際醫學期刊 359篇。(New England Journal of Medicine, JAMA, Nature Medicine, Lancet Diabetes Endocrinology, Annals of Internal Medicine, Circulation, European Heart Journal, JACC, etc.)(Editorial Board): Circulation, JACC-Heart Failure, JACC-Asia (Associated editor), Current Hypertension Report, Journal of Chinese Medical Association, Journal of Arrhythmia, International Journal of Arrhythmia, Journal of Asian Pacific Society of Cardiology
• 國際臨床試驗經驗: 102個
• 53個為臺灣總主持人 (AMISH, AVE/7688 [II], CRESCENDO, YM150 [II], COSIMA 2, LCZ696 [II], RECOVER 2, CEPHEUS, ENGAGE-TIMI 48, SIGNIFY, REALISEAF, T-EMERGE, SAVOR-TIMI 53, LAVENDER, ARTEMIS, ELIXA, Dronedarone PK, TAK-875 304, TAK-875 306, TAK-875 307, ACCELERATE, DECLARE-TIMI 58, ODYSSEY CVOT, CEPHEUS-5S, THEMIS, EINSTEIN CHOICE, GARFIELD-VTE, STRENGTH, ODYSSEY-KT, HARMONY, VICTORIA, ENTRUST, DAPA-HF, BET-MACE, SCORED, DELIVER, SURPASS-CVOT, FINEARTS-HF, Lp(a) HORIZON, MIRACLE, SUMMIT, ENDEAVOR, ORION-18, ZEUS, VICTOR, VICTORION-2 PREVENT, OCEANIC-AF, SURMONT-MMO, LIBREXIA-AF, LIBREXIA-ACS, HERMES, VICTORION-1 PREVENT)
• 23個為全球Steering Committee Member (AMISH, COSIMA 2, CEPHEUS, SIGNIFY, REALISEAF, SAVOR-TIMI53, ACCELERATE, DECLARE-TIMI 58, ODYSSEY, THEMIS, STRENGTH, ROSTAFUROXIN HT trial, VICTORIA,DAPA-HF, SCORED, DELIVER, FINEARTS-HF, Lp(a)HORIZON, ORION-18, ZEUS, OCEANIC-AF, HERMES)
• 臺灣心臟衰竭臨床試驗合作聯盟主席
• 國內外應邀演講: 2006-2022年3614場
• 陽明大學教學績優獎2002-2023年
• 商周98年超推薦百大好醫師                                                                             

• 中華民國內科醫學會
• 中華民國心臟學會
• 中華民國血脂學會
• 美國心電生理學會

        cechiang@vghtpe.gov.tw

1. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098.
2. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 ;381(21):1995-2008.
3. Vardeny O, Fang JC, Desai AS, Jhund PS, Claggett B, Vaduganathan M, de Boer RA, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, Kosiborod MN, DeMets D, O'Meara E, Zieroth S, Comin-Colet J, Drozdz J, Chiang CE, Kitakaze M, Petersson M, Lindholm D, Langkilde AM, McMurray JJV, Solomon SD. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med. 2022 ;28(12):2504-2511.
4. Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang CE, Desai AS, Drożdż J, Hernandez AF, Inzucchi SE, Katova T, Kitakaze M, Kosiborod MN, Lam CSP, Maria Langkilde A, Lindholm D, Bachus E, Martinez F, Merkely B, Petersson M, Saraiva JFK, Shah SJ, Vaduganathan M, Vardeny O, Wilderäng U, Claggett BC, Solomon SD, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022 18;146(16):1210-1224.
5. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 ;323(14):1353-1368.
6. White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Jukema JW, Loy M, Pagidipati N, Pordy R, Ristić AD, Zeiher AM, Wojdyla DM, Steg PG; ODYSSEY OUTCOMES Investigators. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022 ;43(16):1554-1565.
7. Butt JH, Dewan P, Merkely B, Belohlávek J, Drożdż J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Køber L, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Ann Intern Med. 2022;175(6):820-830.
8. Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Willem Borleffs CJ, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Kerr Saraiva JF, Tereschenko SN, Thierer J, Vardeny O, Verma S, Vinh PN, Wilderäng U, Zaozerska N, Lindholm D, Petersson M, McMurray JJV. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. JACC Heart Fail. 2022 ;10(3):184-197.
9. Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chiang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021 ;143(20):1962-1972.
10. Inzucchi SE, Docherty KF, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Verma S, Bělohlávek J, Böhm M, Chiang CE, de Boer RA, Diez M, Dukát A, Ljungman CEA, Bengtsson O, Langkilde AM, Sjöstrand M, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analys From DAPA-HF. Diabetes Care. 2021;44(2):586-594.

限於篇幅,以上謹為代表著作